Website
News25/Ratings12
News · 26 weeks117-32%
2025-10-262026-04-19
Mix8190d
- Other36(44%)
- Insider32(40%)
- SEC Filings7(9%)
- Analyst2(2%)
- Earnings2(2%)
- M&A1(1%)
- Other1(1%)
Latest news
25 items- SECSEC Form 10-Q filed by Johnson & Johnson10-Q - JOHNSON & JOHNSON (0000200406) (Filer)
- PRIMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+Patients achieving sustained minimal symptom expression (MSE) experienced greater improvements in quality of life than those with transient MSE in a post-hoc analysis of the Phase 3 studyEPIC, the first head-to-head study of IMAAVY versus another FcRn blocker in generalized myasthenia gravis, is now enrolling participantsHORSHAM, Pa., April 22, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 3 Vivacity-MG3 study and ongoing open label extension (OLE) in a broad population o
- PRJohnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceJohnson & Johnson (NYSE:JNJ) will participate in the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19th. Management will participate in a Fireside Chat at 11:30 a.m. Eastern Time. This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20260421719308/en/ Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com
- PRJohnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026As Johnson & Johnson celebrates 30 years of CARTO, the launch of CARTOSOUND SONATA brings new AI-based imaging and mapping capabilitiesi to electrophysiology A total of 17 abstracts will be presented, including new clinical data for the VARIPULSE Platform Johnson & Johnson today announced it will showcase the latest advances across its electrophysiology portfolio at the 2026 Heart Rhythm Society (HRS) Annual Meeting, including new evidence in pulsed field ablation (PFA), and innovations in cardiac mapping and imaging. At HRS 2026, the company will launch the CARTOSOUND SONATA Module, leveraging artificial intelligence with the CARTO System to automatically transform intracardiac echoc
- PRThe Infrastructure Play Hiding in Plain Sight Across Cardiac CareVANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The American heart care market is undergoing a structural shift that most retail investors haven't noticed yet. The U.S. cardiovascular devices sector is on track to nearly double, from $22.08 billion in 2025 to $41.29 billion by 2032, fueled by aging demographics and a wave of next-generation diagnostic platforms[1]. At the same time, 75% of U.S. health systems are now rolling out AI-powered clinical tools, with cardiac imaging and documentation leading the charge[2]. That convergence of hardware growth and software integration is creating asymmetric upside for companies building the infra
- PRJohnson & Johnson to Participate in the Bank of America 2026 Healthcare ConferenceJohnson & Johnson (NYSE:JNJ) will present at the Bank of America 2026 Healthcare Conference on Tuesday, May 12th, 2026. Management will participate in a Fireside Chat at 2:20 p.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20260415624527/en/ Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com
- SECJohnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - JOHNSON & JOHNSON (0000200406) (Filer)
- PRJohnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a 3.1% increase in the quarterly dividend, from $1.30 per share to $1.34 per share, marking the 64th year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.36 per share compared to the previous rate of $5.20 per share. The next quarterly dividend is payable on June 9, 2026 to shareholders of record at the close of business on May 26, 2026. The ex-dividend date is May 26, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, tr
- PRJohnson & Johnson reports Q1 2026 results, raises 2026 outlook2026 First-Quarter reported sales growth of 9.9% to $24.1 Billion with operational growth of 6.4%* and adjusted operational growth of 5.3%* 2026 First-Quarter earnings per share (EPS) of $2.14 and adjusted EPS of $2.70 Company increases 2026 guidance with estimated reported sales of $100.8 Billion or 7.0% at the midpoint, and adjusted EPS4 of $11.55 or 7.1% at the midpoint Solidifying path to double-digit growth by the end of the decade, with significant progress for patients with the approvals of ICOTYDE the first-and-only targeted oral peptide for plaque psoriasis, TECVAYLI plus DARZALEX FASPRO as early as second line for patients with relapsed/refractory multiple myeloma, VARIP
- PRJohnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of VisionRobust clinical data, spans two major studies across U.S., Europe and Asia Pacific Data reveals TECNIS PureSee IOL achieved exceptional distance and intermediate vision, low bothersome visual symptoms, high tolerance to post-op refractive errors High patient satisfaction results with TECNIS PureSee IOL Johnson & Johnson (NYSE:JNJ) will present data from two major studies supporting the performance of its recently FDA-approved TECNIS PureSee intraocular lens (IOL) at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 10-13 in Washington, DC. TECNIS PureSee IOL is J&J's next-generation Extended Depth of Focus (EDOF) IOL, which demonstrates excelle
- PRRobotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term ValueAUSTIN, Texas, April 09, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: Pharmaceutical manufacturing is entering a period of structural transformation as regulators impose increasingly stringent expectations around contamination control, data integrity and operational traceability. The European Union's updated GMP Annex 1 guidance places strong emphasis on minimizing human involvement and implementing comprehensive contamination control strategies, requiring manufacturers to evaluate and mitigate risks across personnel, processes and environments. It also encourages the use of barrier systems and automation technologies, reflecting the widely accepted understanding that human oper
- ANALYSTTD Cowen resumed coverage on Johnson & Johnson with a new price targetTD Cowen resumed coverage of Johnson & Johnson with a rating of Buy and set a new price target of $250.00
- PRJohnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in EuropeThe VARIPULSE Pro Platform features a new pulse sequence designed to streamline procedures and enhance workflow efficiencyi,ii VARIPULSE Pro to be featured at EHRA 2026 alongside VARIPURE 12-month interim data Johnson & Johnson (NYSE:JNJ) today announced the launch of VARIPULSE Pro in Europe following CE Mark approval, further advancing its pulsed field ablation (PFA) portfolio. This new pulse sequence marks the next evolution of the VARIPULSE Platform and is designed to improve procedural efficiencyi,ii while reinforcing its established safetyiii and effectivenessiv profile. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026
- PRICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasisJohnson & Johnson presents new data showing high rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studiesNearly 60% of adolescents treated with ICOTYDE achieved completely clear skin at Week 52 in the ICONIC-LEAD studySPRING HOUSE, Pa., March 28, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies, which assessed the efficacy and safety of ICOTYDE™ (icotrokinra) in the treatment of patients with moderate-to-severe plaque psoriasis (PsO). ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.1 These data are b
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Johnson & JohnsonSCHEDULE 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)
- SECAmendment: SEC Form 13F-HR/A filed by Johnson & Johnson13F-HR/A - JOHNSON & JOHNSON (0000200406) (Filer)
- SECAmendment: SEC Form 13F-HR/A filed by Johnson & Johnson13F-HR/A - JOHNSON & JOHNSON (0000200406) (Filer)
- PRFDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptideJohnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pillICOTYDE offers an innovative new option for patients with moderate-to-severe plaque psoriasis to address patients cycling on topical therapies in need of systemic treatmentSPRING HOUSE, Pa., March 18, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40
- PRJohnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancerData presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile Erda-iDRS has the potential to be the first targeted treatment for early–stage bladder cancerRARITAN, N.J., March 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with intermediate-risk and high-risk non–muscle-invasive bladder cancer (NMIBC) whose tumors harbor select fibroblast growth factor receptor (FGFR) alterations. The study met its pri
- INSIDERSEC Form 4 filed by Director Hewson Marillyn A4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERSEC Form 4 filed by Director Pinto Daniel E4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERSEC Form 4 filed by Director Woods Eugene A.4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- PRJohnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients97% of patients reported no very bothersome visual disturbances, like halos or glare, with TECNIS PureSee IOL1 97% of patients would recommend this IOL to friends or family2 TECNIS PureSee IOL is the first and only U.S. FDA-approved extended depth of focus (EDOF) IOL maintaining contrast sensitivity comparable to an aspheric monofocal IOL1* Johnson & Johnson (NYSE:JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract surgery.1 TECNIS PureSee IOL delivers clarity of vision for patients, with 97% of them reporting no very bothersome visual disturbances.1 TECNIS Pure
- SECSEC Form DEFA14A filed by Johnson & JohnsonDEFA14A - JOHNSON & JOHNSON (0000200406) (Filer)
- SECSEC Form DEF 14A filed by Johnson & JohnsonDEF 14A - JOHNSON & JOHNSON (0000200406) (Filer)